A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
The purpose of this study is to assess the difference of safety and efficacy about Capecitabine and S-1 for treatment of patients with low-risk of recurrence after BTC surgery.
Biliary Tract Neoplasms|Recurrence|Cholangiocarcinoma|Gall Bladder Cancer
DRUG: S-1|DRUG: Capecitabine
RFS, recurrence-free survival, RFS was counted from the enrollment to the date on which disease progression or death was detected, or was censored on the last date when progression-free status was confirmed., Enrollment to 1 year
OS, overall survival, OS was calculated from the enrollment to the date of death, or censored on the date of last contact for surviving patients., Enrollment to 3 years
Patients received curative BTC surgery will be informed about the study. After being informed about the study and potential risks, all patients giving written informed consent will undergo a 1-week screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be observed for recurrence of BTC.